Pulmonary hypertension: Difference between revisions
(Created page with "<section begin="radiology" />'''Pulmonary hypertension''' (PH) is defined as elevated blood pressure beyond 20 mmHg MAP in the pulmonary artery (physiological MAP is 10-20). It most commonly occurs as a consequence of heart disease or lung disease. '''Pulmonary arterial hypertension''' (PAH) is one form of pulmonary hypertension which is not due to the above. Pulmonary hypertension is relatively common, the prevalence being approximately 1%, mostly due to the high prev...") |
No edit summary |
||
Line 17: | Line 17: | ||
|Idiopathic | |Idiopathic | ||
Drugs | Drugs | ||
[[Connective tissue disorder]][[Persistent pulmonary hypertension of the newborn]] | |||
[[Connective tissue disorder]] | |||
[[Persistent pulmonary hypertension of the newborn]] | |||
|- | |- | ||
|Group 2 | |Group 2 | ||
Line 60: | Line 63: | ||
For pulmonary arterial hypertension, a calcium channel blocker, phosphodiesterase 5-inhibitor, prostanoid, endothelin receptor antagonist, or guanylate cyclate simulator may be used. | For pulmonary arterial hypertension, a calcium channel blocker, phosphodiesterase 5-inhibitor, prostanoid, endothelin receptor antagonist, or guanylate cyclate simulator may be used. | ||
<noinclude>[[Category:Cardiology]] | <noinclude> | ||
[[Category:Pulmonology]]</noinclude> | [[Category:Cardiology]] | ||
[[Category:Pulmonology]] | |||
</noinclude> |
Revision as of 09:21, 8 July 2024
Pulmonary hypertension (PH) is defined as elevated blood pressure beyond 20 mmHg MAP in the pulmonary artery (physiological MAP is 10-20). It most commonly occurs as a consequence of heart disease or lung disease. Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension which is not due to the above.
Pulmonary hypertension is relatively common, the prevalence being approximately 1%, mostly due to the high prevalence of COPD and heart disease. PH itself can lead to right-sided heart failure.
Etiology and types
We distinguish multiple different types according to the etiology and pathomechanism:
Group | Name | Frequency | Common causes |
---|---|---|---|
Group 1 | Pulmonary arterial hypertension | Rare | Idiopathic
Drugs |
Group 2 | Pulmonary hypertension secondary to left-sided heart disease | Very common | Heart failureValvular disease |
Group 3 | Pulmonary hypertension secondary to lung disease or hypoxaemia | Common | COPDInterstitial lung disease |
Group 4 | Pulmonary hypertension secondary to pulmonary artery obstruction | Rare | Chronic pulmonary embolism |
Group 5 | Pulmonary hypertension secondary to unknown or multifactorial causes | Rare | Chronic kidney diseaseSarcoidosisHaematological disorder |
Clinical features
Exertional dyspnoea is the main symptom. As the hypertension worsens, less and less exertion is required to elicit dyspnoea. Chest pain, cough, and haemoptysis are rare symptoms.
Cyanosis is often present.
Diagnosis and evaluation
Examination for underlying causes may include natriuretic peptide, spirometry, etc.
ECG may show certain unspecific signs, including sinus tachycardia, right axis deviation, P pulmonale, signs of right ventricular hypertrophy, or RBBB.
Neither chest radiography or CT are required in the evaluation, except for evaluation of underlying disorders. On x-ray, the central vessels may be more prominent than normal. On CT, one can see that the pulmonary artery is larger than the ascending aorta, and that there is a so-called centroperipheral caliber discrepancy or “pruning” of the peripheral vessels, which means that the central pulmonary vessels are larger than normal while the peripheral vessels aren't.
Echocardiography is obligatory for the evaluation, as it can estimate the pulmonary artery pressure. However, right heart catheterisation is obligatory for the final diagnosis, as it can directly measure the pressure.
Management
Regardless of type and cause, hypoxaemia will worsen the condition and should be avoided.
Lung-protective lifestyle changes, including weight loss, smoking cessation, and avoidance of pollutants and microbes, is always indicated. If due to an underlying disease, this should be treated. It's important to reduce
For pulmonary arterial hypertension, a calcium channel blocker, phosphodiesterase 5-inhibitor, prostanoid, endothelin receptor antagonist, or guanylate cyclate simulator may be used.